Capital expenditure · 2011–2025
Biomarin Pharmaceutical capital expenditure
$103M+20.6% · FY2025
Biomarin Pharmaceutical (BMRN) reported $103M in capital expenditure for fiscal 2025, +20.6% year on year.
| Fiscal year | Capital expenditure | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $103M | +20.6% | Open → |
| FY20242024-12-31 | $85.4M | −11.7% | Open → |
| FY20232023-12-31 | $96.7M | −20.1% | Open → |
| FY20222022-12-31 | $121M | +26.6% | Open → |
| FY20212021-12-31 | $95.6M | −16.4% | Open → |
| FY20202020-12-31 | $114M | −21.2% | Open → |
| FY20192019-12-31 | $145M | +0.3% | Open → |
| FY20182018-12-31 | $145M | −27.4% | Open → |
| FY20172017-12-31 | $199M | +34.3% | Open → |
| FY20162016-12-31 | $148M | −34.8% | Open → |
| FY20152015-12-31 | $228M | +94.5% | Open → |
| FY20142014-12-31 | $117M | +79.6% | Open → |
| FY20132013-12-31 | $65.2M | +46.3% | Open → |
| FY20122012-12-31 | $44.6M | −39.1% | Open → |
| FY20112011-12-31 | $73.2M | — | Open → |
Capital expenditure — Capital expenditure is the cash the company spent during the year on property, plant and equipment — factories, stores, servers, vehicles. It appears in the investing section of the cash-flow statement as an outflow and is shown here as a positive amount. Operating cash flow minus this figure is free cash flow.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +2.5%
Capital expenditure at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Biomarin Pharmaceutical capital expenditure |url=https://companiesranked.com/en/company/biomarin-pharmaceutical/capital-expenditure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Biomarin Pharmaceutical capital expenditure. CompaniesRanked. https://companiesranked.com/en/company/biomarin-pharmaceutical/capital-expenditureBibTeX
@misc{companiesranked-en-company-biomarin-pharmaceutical-capital-expenditure-2026,
author = {{CompaniesRanked}},
title = {{Biomarin Pharmaceutical capital expenditure}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/biomarin-pharmaceutical/capital-expenditure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001048477-26-000004 · February 26, 2026
{{cite web |title=Biomarin Pharmaceutical capital expenditure — 10-K (0001048477-26-000004) |url=https://www.sec.gov/Archives/edgar/data/1048477/000104847726000004/bmrn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-26}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.